Featured Publications

Leveraging a deep bench of expertise and foundational experience in DNA medicine development, we’re driving research that has the potential to transform treatment paradigms and improve patients’ lives.

Vaccines for HPV-associated diseases

Molecular Aspects of Medicine
December 2023

Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis

Laryngoscope
May 2023

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

The Journal of Infectious Diseases
January 2022

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster

Open Forum Infectious Diseases
December 2021

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants

npj Vaccines
October 2021

Immunogenicity of a DNA vaccine candidate for COVID-19

Nature Communications
May 2020

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet
September 2015

DMAb™ (DNA-Encoded Monoclonal Antibodies)

Title	Disease Target	Product
Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge Human Vaccines & Immunotherapeutics — December 2019	Zika	INO-A002
In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus Molecular Therapy — April 2019	Zika	INO-A002
In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model Cell Reports — November 2018	Ebola
Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo Cancer Research — November 2018	CTLA-4
Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody Cancer Immunology, Immunotherapy — August 2017	Prostate Cancer
DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections npj Vaccines — July 2017	Influenza

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases